Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, Lehmann L, Miloslavsky M, Hume R, Hannah AL, Nejadnik B, Soiffer RJ. Richardson PG, et al. Among authors: hannah al. Br J Haematol. 2017 Jul;178(1):112-118. doi: 10.1111/bjh.14727. Epub 2017 Apr 26. Br J Haematol. 2017. PMID: 28444784 Free PMC article.
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.
Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, Arai S, Grupp SA, Guinan EC, Martin PL, Steinbach G, Krishnan A, Nemecek ER, Giralt S, Rodriguez T, Duerst R, Doyle J, Antin JH, Smith A, Lehmann L, Champlin R, Gillio A, Bajwa R, D'Agostino RB Sr, Massaro J, Warren D, Miloslavsky M, Hume RL, Iacobelli M, Nejadnik B, Hannah AL, Soiffer RJ. Richardson PG, et al. Among authors: hannah al. Blood. 2016 Mar 31;127(13):1656-65. doi: 10.1182/blood-2015-10-676924. Epub 2016 Jan 29. Blood. 2016. PMID: 26825712 Free PMC article. Clinical Trial.
Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, Lehmann L, Shore T, Iacobelli M, Miloslavsky M, Hume R, Hannah AL, Nejadnik B, Soiffer RJ; Defibrotide Study Group. Richardson PG, et al. Among authors: hannah al. Biol Blood Marrow Transplant. 2017 Jun;23(6):997-1004. doi: 10.1016/j.bbmt.2017.03.008. Epub 2017 Mar 8. Biol Blood Marrow Transplant. 2017. PMID: 28285079 Free article.
A strategic framework for novel drug development in multiple myeloma.
Anderson KC, Hannah AL, Pazdur R, Farrell AT. Anderson KC, et al. Among authors: hannah al. Br J Haematol. 2007 Jul;138(2):153-9. doi: 10.1111/j.1365-2141.2007.06641.x. Br J Haematol. 2007. PMID: 17593022 Free article. Review. No abstract available.
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME, Sugarman S, Ma W, Patil S, Norton L, Hannah AL, Hudis C. Modi S, et al. Among authors: hannah al. Clin Cancer Res. 2011 Aug 1;17(15):5132-9. doi: 10.1158/1078-0432.CCR-11-0072. Epub 2011 May 10. Clin Cancer Res. 2011. PMID: 21558407 Clinical Trial.
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, Cherrington JM, O'Farrell AM, Yuen HA, Louie SG, Hong W, Cortes JE, Verstovsek S, Albitar M, O'Brien SM, Kantarjian HM, Karp JE. Giles FJ, et al. Among authors: hannah al. Blood. 2003 Aug 1;102(3):795-801. doi: 10.1182/blood-2002-10-3023. Epub 2003 Mar 20. Blood. 2003. PMID: 12649163 Free article. Clinical Trial.
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.
Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Tripathy D, et al. Among authors: hannah al. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. doi: 10.1001/jamaoncol.2022.0514. JAMA Oncol. 2022. PMID: 35552364 Free PMC article. Clinical Trial.
ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.
Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Dieras V, Müller V, Tagliaferri M, Hannah AL, Cortés J. Tripathy D, et al. Among authors: hannah al. Future Oncol. 2019 Jul;15(19):2211-2225. doi: 10.2217/fon-2019-0180. Epub 2019 May 10. Future Oncol. 2019. PMID: 31074641 Free PMC article. Clinical Trial.
56 results